Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The brain-enriched guanylate kinase-associated protein (BEGAIN) is a cytosolic protein mainly expressed in the brain, where it likely supports or maintains the structure of the postsynaptic density (PSD) in neurons[1]. The PSD is a protein-dense specialization found at the postsynaptic membrane of synapses and is crucial for synaptic signaling and plasticity. Although BEGAIN is closely associated with this structure, its detailed molecular function remains incompletely characterized. BEGAIN is not classified as a receptor, enzyme, transporter, or transcription factor, and there are no known interacting drugs, disease associations, or biomarker roles documented in public antibody or structural protein databases[1]. If you require more detailed protein sequence or structural data, refer to specialized resources such as UniProt, NCBI Gene, or antibody product databases under "KIAA1446" or "BEGAIN."
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Brain-enriched guanylate kinase-associated protein (BEGAIN).